Multivariable Cox proportional hazard models. TAPSE adjusted for clinical, echocardiographic, and hemodynamic variables.
| TAPSE | Adjusted HR for Death (95% CI) | p |
|---|---|---|
| Measure | ||
| NYHA FC | 3.35 (1.13–9.90) | 0.03 |
| Baseline therapy* | 4.43 (1.46–13.4) | < 0.01 |
| Echocardiography | ||
| RVFAC, % | 5.25 (1.41–19.4) | 0.01 |
| RAA index | 2.44 (0.74–8.11) | 0.14 |
| Diastolic eccentricity index | 2.61 (0.84–8.08) | 0.09 |
| Maximum TR jet velocity | 4.54 (1.02–20.1) | 0.05 |
| Pericardial effusion | 3.82 (1.31–11.2) | 0.01 |
| Hemodynamics | ||
| RAP | 3.12 (1.02–9.58) | 0.05 |
| CI | 3.60 (1.09–11.9) | 0.04 |
| PVR | 2.27 (0.69–7.48) | 0.18 |
| SV/PP | 3.41 (1.12–10.4) | 0.03 |
| SVI | 3.41 (1.10–10.6) | 0.03 |
| PA saturation | 3.13 (0.90–10.8) | 0.07 |
↵* Baseline therapy refers to use of PAH-specific therapy (phospho-diesterase type 5 inhibitor, endothelin receptor antagonist, prostacyclin analog). TAPSE: tricuspid annular plane systolic excursion; NYHA FC: New York Heart Association functional class; RVFAC: right ventricular fractional area change; RAA: right atrial area; TR: tricuspid regurgitant; RAP: right atrial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; SV/PP: stroke volume/pulse pressure; SVI: stroke volume index; PA: pulmonary artery.